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Abdominal aortic aneurysm (AAA), an inflammatory disease, involves leukocyte recruitment, immune responses, inflammatory cytokine production, vascular remodeling, neovascularization, and vascular cell apoptosis,
all of which contribute to aortic dilatation. This study demonstrates that mast cells, key participants in human
allergic immunity, participate in AAA pathogenesis in mice. Mast cells were found to accumulate in murine
AAA lesions. Mast cell–deficient KitW-sh/KitW-sh mice failed to develop AAA elicited by elastase perfusion or periaortic chemical injury. KitW-sh/KitW-sh mice had reduced aortic expansion and internal elastic lamina degradation;
decreased numbers of macrophages, CD3+ T lymphocytes, SMCs, apoptotic cells, and CD31+ microvessels; and
decreased levels of aortic tissue IL-6 and IFN-γ. Activation of mast cells in WT mice via C48/80 injection resulted
in enhanced AAA growth while mast cell stabilization with disodium cromoglycate diminished AAA formation. Mechanistic studies demonstrated that mast cells participated in angiogenesis, aortic SMC apoptosis, and
matrix-degrading protease expression. Reconstitution of KitW-sh/KitW-sh mice with bone marrow–derived mast
cells from WT or TNF-α–/– mice, but not from IL-6–/– or IFN-γ–/– mice, caused susceptibility to AAA formation to
be regained. These results demonstrate that mast cells participate in AAA pathogenesis in mice by releasing proinflammatory cytokines IL-6 and IFN-γ, which may induce aortic SMC apoptosis, matrix-degrading protease
expression, and vascular wall remodeling, important hallmarks of arterial aneurysms.
*OUSPEVDUJPO
Abdominal aortic aneurysm (AAA), a common aortic disease in
the elderly, with an unknown pathogenesis, is characterized by
extensive tissue remodeling, neovascularization, inflammatory cell
infiltration, and vascular cell apoptosis, all of which contribute
to aortic dilatation, the sine qua non of the disease (1). Leukocyte recruitment is a key feature of human AAA. After infiltration,
the neutrophils, macrophages, and lymphocytes in human AAA
lesions produce a spectrum of proinflammatory cytokines and
matrix-degrading proteases that promote formation of AAA (1).
Selective depletion of neutrophils (2), lymphocytes (3), matrixdegrading proteases (4, 5), or proinflammatory cytokines (6)
impairs experimental AAA formation.
Mast cells are another inflammatory cell type recently identified
in human aortic lesions, including those of atherosclerosis and AAA
(7, 8). Classically, mast cells have been described as essential effector
cells of immediate hypersensitivity and chronic allergic reactions that
contribute to asthma, atopic dermatitis, and other allergic diseases
(9). Despite the lack of direct evidence of mast cell participation in
either atherosclerosis or AAA, enhanced accumulation of mast cells
during human atherogenesis and AAA formation suggests that mast
Nonstandard abbreviations used: AAA, abdominal aortic aneurysm; BMMC, bone
marrow–derived mast cell; DSCG, disodium cromoglycate; IEL, internal elastic lamina;
MCP-1, monocyte chemoattractant protein–1; PDTC, pyrrolidine dithiocarbamate.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 117:3359–3368 (2007). doi:10.1172/JCI31311.
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cells play a role in the pathogenesis of these vascular diseases. For
example, active chymase, a unique mast cell protease important in
the formation of angiotensin II and activation of MMP (10, 11), has
been found at increased levels in extracts of human AAA lesions. Chymase-positive mast cells were detected in the media and adventitia
in human AAA (8). Pharmacological inhibition of chymase activity
reduces AAA progression in hamsters (12). In addition to a unique
set of proteases, mast cells also release proinflammatory cytokines
(IFN-γ, TNF-α, and IL-4, -5, -6, and -13) and chemokines (monocyte
chemoattractant protein–1 [MCP-1], IL-8, RANTES), all of which
may directly or indirectly participate in AAA formation. Stabilization of mast cells with disodium cromoglycate (DSCG) blocked the
increase of plasma IL-6 in ApoE–/– mice (13). Many in vitro and in
vivo studies have also demonstrated that IL-6 plays a role in lymphocyte activation and that IFN-γ stimulates lymphocytes, macrophages,
ECs, and fibroblasts. In addition to activating T cells and B cells, IL-6
is required for fibroblast and EC MCP-1 expression, macrophage and
leukocyte recruitment, MMP expression, angiogenesis, angiotensin
II–mediated macrophage oxidized LDL uptake, and angiotensin
II–mediated reactive oxygen species production and endothelial dysfunction, all of which are important to AAA pathogenesis (7). Mice
lacking IFN-γ are resistant to AAA (3). Injection of IFN-γ into CD4+
T cell–depleted mice, which are resistant to aneurysm induction, can
partially reconstitute aneurysms in CD4–/– mice (3).
However, other inflammatory cell types in AAA lesions, such as
macrophages, neutrophils, and lymphocytes, also produce potent
extracellular matrix proteases as well as the aforementioned mast
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cell mediators. For example, macrophages are a major source of
the vascular wall destructive cysteine proteases (14), MMP (4, 5),
and the proinflammatory cytokines TNF-α, IL-1β, and IFN-γ (3,
15), implicated in the development of human and murine AAA.
Lymphocytes produce Th1 and Th2 cytokines in human arterial
diseases (3, 15). Our recent studies demonstrated that CD4+ T
cells, the major lymphocytes in human AAA lesions (3), produce
MMP-9 and the cysteine proteases cathepsins S, K, and L (16), all
of which are essential to vasculature remodeling (4, 14).
In this study, we used an aorta elastase perfusion–initiated
mouse AAA model to determine whether mast cells modulate AAA
formation. Reconstitution of mast cells from different cytokinedeficient mice into mast cell–deficient mice identified mast cell
mediators essential to AAA. Finally, we determined whether we
can regulate mouse AAA formation by activating or stabilizing
mast cell activities in vivo.
3FTVMUT
Mast cell accumulation and AAA formation. Biochemical observations
revealed high numbers of chymase- and tryptase-positive mast cells
in human AAA lesions and suggested an association of mast cell
accumulation and AAA progression (8). To test this hypothesis, we
used an established elastase perfusion model to produce AAA in
mice (2, 4). In this model, the infrarenal aorta is locally exposed to
pancreatic elastase, and aortic expansion forms over a period of 2
weeks as defined by an increase of aortic diameter by 100% greater
than that before perfusion (4). Consistently, all mice developed
AAA 14 days after elastase perfusion (Figure 1A). While normal
aortas contained few if any mast cells (Figure 1, B and E), a significant increase of mast cell content appeared in the adventitia 7
days after perfusion (Figure 1, C and E) with further increase at 14
days after perfusion (Figure 1, D and E). Murine mast cells appear
predominantly in the adventitia (Figure 1, C and D). These obser
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vations indicate that mast cells populate AAA induced by elastase
perfusion and provide an opportunity to determine experimentally whether AAA formation requires mast cells.
Reduced AAA in mast cell–deficient mice. Accumulation of mast cells
in AAA lesions suggests a participation of these cells in this disease.
To test this hypothesis, we studied mast cell–deficient KitW-sh/KitW-sh
mice in the elastase perfusion–induced AAA model. KitW-sh/KitW-sh
mice contain a de novo inversion mutation consisting of a break
point at the upstream regulatory region of the c-kit receptor gene
that results in reduced Kit receptor expression and defective mast
cell maturation and survival (17). However, this mutation does
not affect the number or function of blood leukocytes, including lymphocytes (18). Elastase activities of bone marrow–derived
neutrophils (6,185 ± 94 versus 6,195 ± 26, OD515nm; P = 0.92) and
blood monocytes (5,980 ± 167 versus 6,274 ± 62, OD515nm; P = 0.18)
showed no significant difference between WT mice and KitW-sh/
KitW-sh mice. At baseline, histological analysis did not reveal any
aortic wall elastin degradation, loss of medial SMCs, medial SMC
apoptosis, or infiltration of macrophages and T cells in aortas
from either WT or KitW-sh/KitW-sh mice before the elastase perfusion
(data not shown). However, KitW-sh/KitW-sh mice were protected from
AAA formation during 56 days following elastase perfusion. After
perfusion expansion (day 0), the abdominal aortas of KitW-sh/KitW-sh
mice showed no further expansion on days 7, 14, and 56, whereas
all WT control mice had an average of more than 110% and approximately 170% aortic expansion 14 and 56 days after perfusion,
respectively (Figure 2A). Importantly, while the lumen diameters
of both WT and KitW-sh/KitW-sh mice increased at day 0 by nearly 30%
due to elastase perfusion, the lumen diameters of KitW-sh/KitW-sh
mice decreased continuously to those of preperfusion at day 56
after perfusion. In contrast, although there was a decrease on
day 7, lumen diameters of WT mice increased consistently over
time and reached 30% at day 56 after perfusion (Figure 2B).
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Therefore, the AAA protection in KitW-sh/KitW-sh mice at day 14
was largely due to attenuation of adventitial thickening, whereas AAA protection in KitW-sh/KitW-sh mice at 56 days was the result
of a combination of attenuation of both luminal expansion and
adventitial thickening. Histological analysis of KitW-sh/KitW-sh mice
showed better preservation of the internal elastic laminae (IELs)
(Figure 2C), consistent with higher medial SMC content on day
14, as determined by semiquantitative grading (Figure 2D). Therefore, reduced levels of medial SMCs in WT mice may result from
enhanced IEL fragmentation and an increase in medial SMC death.
Although most mast cells reside in the adventitia, clusters of mast
The Journal of Clinical Investigation

cells exist in the media where elastin degradation and SMC apoptosis occur. Immunostaining of serial sections with mouse MCP-4
(mMCP-4) (mast cells) (19) and α-actin (SMCs) demonstrated
numerous mast cells but fewer SMCs in the media (Figure 2E),
suggesting a role of mast cells in medial SMC apoptosis. Further,
activated mast cells in the adventitia may also release granular contents capable of acting on cells at a distance, such as those in the
media. Compared with KitW-sh/KitW-sh mice, WT mice showed overall more apoptotic cells on days 7 and 14 (∼4-fold) (Figure 2F).
By staining adjacent sections for both SMCs (α-actin) (Figure 2G)
and apoptosis (TUNEL) (Figure 2H), we explored the contribution
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of cell death to the loss of medial SMCs. Media poor in α-actin had
abundant TUNEL staining. Significantly reduced levels of macrophages (Figure 2I) and CD3+ T cells (Figure 2J) in elastase-perfused
KitW-sh/KitW-sh mice confirmed decreased inflammation.
Neovascularization plays an essential role in AAA formation, and
its presence associates with AAA lesion rupture (20). To determine
whether mast cells modulate neovascularization, we stained tissue
sections with an anti-CD31 antibody and found a reduced content
of adventitial CD31+ microvessels in KitW-sh/KitW-sh mice both 7 and

14 days after elastase infusion (Figure 2K). Immunostaining of
AAA serial sections from WT mice with mMCP-4 and CD31 antibodies demonstrated the presence of both microvessels and mast
cells in the adventitia (Figure 2L), indicating a possible interaction
between mast cells and ECs.
Observations from the KitW-sh/KitW-sh mice show that mast cells
regulate AAA formation and suggest that they do so by modulating
directly or indirectly the level of cellular inflammation, angiogenesis, and SMC apoptosis in aortic wall. However, the present data do
not exclude the possibility that the reduced inflammation observed
resulted from decreased AAA formation rather than the converse.
Mast cells promote periaortic CaCl2-induced AAA formation. To further
test the hypothesis of mast cell participation in AAA pathogenesis,
we induced AAA formation in WT and KitW-sh/KitW-sh mice using a
second model of experimental AAA (5). Six weeks after periaortic
CaCl2 injury, aortic diameter in WT mice increased more than 70%.
In contrast, KitW-sh/KitW-sh mice showed a less than 25% increase in
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aortic diameter (Figure 3A) and preservation of the IEL (Figure 3B).
Under these experimental conditions, no lumenal changes were
noticed in WT mice 6 weeks after injury and absence of mast
cells had no effect on lumen diameters. Our data presented in
Figure 3, A and B, indicate that the prevention of AAA formation
in KitW-sh/KitW-sh mice is independent of the animal models used.
Mast cell IL-6 and IFN-γ contribute to AAA formation. In KitW-sh/KitW-sh
mice, protection from AAA formation may result either from
altered c-kit signaling caused by the inversion mutation of the
c-kit receptor gene or the absence of mast cells. To differentiate
these possibilities, we introduced bone marrow–derived mast
cells (BMMCs) from WT mice and mice deficient in mast cell
cytokines IL-6, IFN-γ, and TNF-α into the tail veins of KitW-sh/KitW-sh
mice using an established protocol (18, 19, 21, 22), followed by
elastase perfusion to induce AAA formation. Reconstitution
The Journal of Clinical Investigation

with WT BMMCs largely restored AAA formation and inflammatory cell (macrophages) infiltration in KitW-sh/KitW-sh mice 14 days
after elastase perfusion (Figure 4, A and B), confirming that the
absence of mast cells, rather than altered c-kit signaling, protects
KitW-sh/KitW-sh mice from AAA formation. Despite TNF-α’s role in
mediating some forms of mast cell–associated inflammation (23),
KitW-sh/KitW-sh mice reconstituted with TNF-α–deficient BMMCs
developed AAA and enhanced macrophage accumulation similar
to those achieved with WT BMMCs. In contrast, BMMCs from
IL-6– or IFN-γ–deficient mice did not have these effects (Figure 4,
A and B). Failed restoration of AAA in KitW-sh/KitW-sh mice reconstituted with IL-6– and IFN-γ–deficient BMMCs did not result from
altered maturation of IL-6– or IFN-γ–deficient BMMCs. Granular
morphology, tryptase production, and cell-surface expression of
FcεR of IL-6– and IFN-γ–deficient BMMCs did not differ from
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those of WT BMMCs (19). Further, immunostaining with antibodies against mouse chymase mMCP-4 demonstrated that the
accumulation of IL-6– or IFN-γ–deficient mast cells that appeared
in reconstituted KitW-sh/KitW-sh mouse abdominal aortas 14 days
after perfusion (19.3 ± 7.4 and 24.5 ± 3.7 mast cells/mm2, respectively) did not differ significantly from that in abdominal aortas of
WT or TNF-α–deficient BMMC-reconstituted KitW-sh/KitW-sh mice
(29.7 ± 6.8 and 20.2 ± 4.9 mast cells/mm2, respectively), indicating
similar recruitment of the IL-6– and IFN-γ–deficient mast cells to
the abdominal aortas following elastase perfusion. Therefore, mast
cell–derived IL-6 and IFN-γ may play key roles in aortic remodeling and expansion. In agreement with this hypothesis, aortas from
KitW-sh/KitW-sh mice and those reconstituted with IFN-γ– and IL-6–
deficient BMMCs had significantly fewer IFN-γ–positive areas
than those in aortic lesions from KitW-sh/KitW-sh mice reconstituted
with WT or TNF-α–deficient BMMCs (Figure 4, C and D). The
AAA tissue extract ELISA detected significant reduction of IL-6 in
KitW-sh/KitW-sh mice relative to WT mice (Figure 4E). Therefore, from
these experiments, we conclude that mast cell–derived IL-6 and
IFN-γ play key roles in aortic remodeling and expansion.
Control of AAA by regulating mast cell activation. Activation of mast
cells and the subsequent release of their granular constituents is a
major mechanism whereby mast cells participate in pathobiological
processes (24). Mast cells likely affect AAA pathogenesis by releasing IL-6, IFN-γ (Figure 4, A–E), and possibly other unmeasured
molecules. Therefore, blocking IL-6 and IFN-γ release might control AAA formation, a hypothesis tested in atherosclerotic apoEdeficient mice (13). To determine whether regulation of mast cell
activation controls AAA formation, we injected compound 48/80
(C48/80, 4 mg/kg/d), a mast cell degranulation agent, or DSCG
(25 mg/kg/d), a mast cell stabilizer, i.p. during AAA formation. In
WT mice, mast cell activation induced by C48/80 increased aortic
expansion by 40% (Figure 4F). In contrast, the mast cell stabilizer
DSCG reduced aortic expansion by 40%, suggesting that reduced
mast cell degranulation limits AAA development. Further, increased
AAA in C48/80-treated mice and decreased AAA in DSCG-treated
mice corresponded with changes in IEL fragmentation (Figure 4G),
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suggesting that mast cells regulate the activities of aortic elastases.
Importantly, increased lesion sizes in C48/80-treated mice accompanied enhanced lesion macrophage contents (Figure 4B) but did
not alter lesion mast cell accumulation as detected by mMCP-4
immunostaining (Figure 4H), suggesting that C48/80 promotes
mast cell activation or degranulation and thereby augments the
release of mast cell mediators. Immunohistological analysis and
ELISA of AAA tissue extracts from C48/80-treated mice revealed
significantly higher levels of both IFN-γ (Figure 4, C and D) and IL-6
(Figure 4E), which could be the result of mast cell activation/degranulation by C48/80. In contrast, impaired AAA lesions in DSCGtreated mice also showed reduced mast cell numbers (Figure 4H),
macrophage contents (Figure 4B), and lesional IFN-γ (Figure 4,
C and D) and IL-6 (Figure 4E) levels, suggesting DSCG affects
AAA beyond mast cell stabilization, possibly via an antiinflammatory effect (25). Alternatively, altered lesion macrophage contents
and IFN-γ and IL-6 levels could also be secondary to corresponding changes of AAA lesion formation in C48/80- or DSCG-treated
mice. Nevertheless, our data demonstrate an impact of C48/80 and
DSCG in AAA growth and reveal a potential novel target for AAA
prevention and management in humans.
Expression of elastinolytic cathepsins and MMPs in mouse AAA. Elastases play essential roles in arterial wall remodeling, including
atherosclerosis and AAA. Deficiencies in elastinolytic cathepsins
S (26), K (27), and L (16) reduce atherogenesis in mice. Mice deficient in cathepsins C (28) or S (unpublished data) and MMP-9 or
MMP-2 (4, 5) also develop significantly less AAA in experimental
models. Mast cells release a unique set of proteases, i.e., tryptase
and chymase, that may participate in AAA directly or indirectly
by activating MMP (11). Our recent in vitro study demonstrates
that mast cells induce elastinolytic cathepsin expression in both
aortic SMCs and ECs (19). Labeling the cysteine protease active
site with [125I]JPM (29) (Figure 5, A and B) and determining MMP
activity by gelatin zymography (Figure 5, A and C) (30) revealed
much lower cathepsin and MMP activities in aortic extracts from
Kit W-sh/Kit W-sh mice than in WT mice 14 days after elastase
perfusion. Importantly, the activities of cathepsin and MMP in

http://www.jci.org

Volume 117

Number 11

November 2007

Downloaded on August 12, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/31311

SFTFBSDIBSUJDMF
the aortas of KitW-sh/KitW-sh mice increased following reconstitution
with BMMCs from WT or TNF-α–deficient mice but not those
from IL-6– or IFN-γ–deficient mice (Figure 5, B and C), suggesting
that mast cell–derived IL-6 and IFN-γ stimulate matrix-degrading
protease IEL degradation (Figure 4, F and G). These observations
agree with prior in vitro studies (19). BMMCs from IL-6- or IFN-γ–
deficient mice produce less than 5% IL-6 or IFN-γ of those from WT
mice. In contrast, BMMCs from TNF-α–deficient mice release 50%
IL-6 and 30% IFN-γ of those from WT mice and thus may suffice
to induce vascular cell protease expression in vitro (19) and in vivo
(Figure 5, B and C). Activities of both cathepsin (e.g., cathepsin B)
and MMP (e.g., MMP-2) increased in aortic extracts from C48/80treated mice but decreased to the levels found in KitW-sh/KitW-sh
mice following the stabilization of mast cells with DSCG (Figure 5,
A–C) when both assays contained an equal amount of proteins
(Figure 5A). In situ elastin zymography optimized for cysteine
proteases (pH 5.5 with both EDTA and dithiothreitol) supported
these observations. While negligible elastinolytic activities (green
fluorescence in the adventitia) were detected in normal aorta,
saline-treated aorta, and heat-inactivated elastase–treated aorta,
AAA lesions in WT mice showed much higher elastinolytic activity
than did those from KitW-sh/KitW-sh mice, as indicated by the differences in percentage area of adventitia fluorescence in Figure 5D.
Media green fluorescence may come from both increased elastase
activity in AAA lesions and intact elastin filament autofluorescence, which also appeared in normal aorta and in experiments
in which elastin substrate was not utilized (Figure 5D). The nonselective cathepsin inhibitor E64d (20 μM) greatly inhibited such
activity in parallel sections. Increased AAA expansion (Figure 4F)
and IEL fragmentation (Figure 4G) in mice treated with the mast
cell activator C48/80 accompanied enhanced in situ activity of
cathepsin elastase. Likewise, impaired AAA and reduced IEL
degradation in DSCG-treated mice (Figure 4, F and G) may have
resulted, at least in part, from a reduction in elastinolytic cathepsin activity (Figure 5D). Omission of fluorogenic elastin substrate
was utilized for the control (Figure 5D).
Role of mast cells in neovascularization and aortic SMC apoptosis.
Angiogenesis and apoptosis, like elastinolysis, are common in
human AAA (20). Inhibition of angiogenesis or apoptosis reduces
AAA formation in rodents (31, 32). In KitW-sh/KitW-sh mice, decreases
in the number of microvessels (Figure 2K) and total apoptotic
cells (Figure 2F) suggest that mast cells participate in these pathologic events. After incubating mouse aortic rings in Matrigel with
degranulated mast cell supernatant from WT mice (Figure 6,
B and C) but not after incubation with culture medium alone
(Figure 6, A and C), microvessel sprouting, similar to that seen in
the aortic rings treated with IL-6–, IFN-γ–, and TNF-α–deficient
mast cell supernatant (data not shown), occurred at substantial
levels, suggesting that additional factors from mast cells contributed to microvessel growth in AAA. Immunostaining a cross
section of the Matrigel with mouse CD31 antibody revealed wellformed microvessels derived from the aorta after stimulation with
medium conditioned by mast cell degranulation (Figure 6D).
α-Actin staining of SMCs of AAA lesions in WT mice showed
areas negative for α-actin (Figure 2G) but rich in apoptotic cells
(Figure 2H) in contrast to reduced apoptotic cells in lesions of
KitW-sh/KitW-sh mice (Figure 2F), consistent with a role of mast cells
in aortic SMC apoptosis (33). To identify mast cell–derived mediators important for SMC apoptosis, we used pyrrolidine dithiocarbamate (PDTC) with or without supernatant from degranulated
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BMMCs to induce apoptosis of mouse aortic SMCs. TUNELpositive cells appeared within hours. However, supernatant from
degranulated BMMCs from WT and TNF-α–deficient mice but not
that from IL-6– and IFN-γ–deficient mice enhanced SMC apoptosis (Figure 6, E and F), supporting a role of mast cell–derived IL-6
and IFN-γ in aortic SMC apoptosis.
%JTDVTTJPO
Although mast cells have been identified in human AAA lesions, evidence for a direct participation of mast cells in this vascular disease is
lacking. The availability of mast cell–deficient mice and established
mouse AAA models made it possible to determine whether these
cells are essential mediators of AAA and not merely a hallmark.
This study used a BMMC reconstitution technique to determine
whether mast cell–derived IL-6, IFN-γ, and TNF-α play a role in
AAA formation (Figure 4A). TNF-α is expressed in macrophages
and lymphocytes both in the atherosclerotic (34) and AAA (35)
lesions. In ApoE–/– mice with diet-induced atherosclerosis, a lack
of TNF-α reduces atherosclerosis (36). In this model, TNF-α plays
a proatherogenic role by upregulating expression of the vascular
adhesion molecules ICAM-1 and VCAM-1 and the chemokine
MCP-1 in the vascular wall and by inducing expression of scavenger receptor class A and uptake of oxidized LDLs in macrophages.
Although it remains to be determined whether TNF-α plays a similar role to that in atherosclerosis, both serum (37) and aneurysmal
tissues (35) from AAA patients have increased TNF-α levels. However, our data with TNF-α–/– mast cells did not support a direct
role of mast cell–derived TNF-α in AAA. This does not exclude the
possibility that TNF-α plays a role in AAA formation; rather, it is
possible that TNF-α produced from other cells may compensate
for its absence from mast cells.
AAA formation requires mast cell IFN-γ and IL-6 but not TNF-α.
Reconstitution of mast cell–deficient KitW-sh/KitW-sh mice with
IFN-γ–/– or IL-6–/– BMMCs did not restore the AAA phenotype
(Figure 4A). These observations agree with the findings in IFN-γ–/–
mice (3), which are protected from CaCl2-induced AAA. Both this
study (3) and others using a histocompatibility-mismatched aortic
transplantation model in IFN-γ receptor–deficient recipient mice
(6) demonstrated that Th2-slanted immune responses promote
AAA formation. Indeed, mast cells from IL-6–/– and IFN-γ–/– mice
produce negligible IFN-γ and IL-6, suggesting cooperative regulation of these 2 cytokines (19). HeLa cells and monocytes exhibit
IFN-γ–regulated expression of IL-6 (38, 39). Enhanced IL-6 and
IFN-γ, which may come in part from mast cells, were detected in
cultured explants of human AAA lesions and in serum of AAA
patients (15, 40). AAA sections or tissue extracts from WT mice
contained much higher levels of both IFN-γ and IL-6 than those
from KitW-sh/KitW-sh mice (Figure 4, C–E). In addition to their possible
roles in activating macrophages and inducing MMP and cysteine
protease expression (41), which are also critical to AAA formation
(4, 5), IL-6 and IFN-γ appeared to regulate the formation of AAA
by modulating lesional SMC apoptosis (Figure 6, E and F). Our
observations from in vitro cell-based assay and the murine AAA
model not only demonstrate that mast cell–derived IL-6 and IFN-γ
are essential to AAA but also suggest that other sources of IL-6 and
IFN-γ, e.g., inflammatory cells such as T cells (3) and macrophages
(42), do not compensate for their absence in mast cells. Such cell
type–dependent functional specificity is not unique to IL-6 and
IFN-γ, as similar activity has been reported for other cytokines. For
example, mast cell TNF-α is required for recruiting neutrophils to
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infected tissue compartments (43), macrophage and neutrophil
TNF-α are required for resistance to intracellular Listeria infection,
and T cell TNF-α is required for protection from high bacterial
loads (44). Thus, while it may seem intuitive that, because cytokines
are made by many cell types, the absence of their production by one
cell type would be compensated for by their production by another
cell type, when tested in experimental models, this compensation
does not always prove to be true, and depending on the end point
measured, a single cellular source of a cytokine can have profound
influence over modulating that end point.
Our in vitro experiments demonstrate that mast cell–derived
IL-6 and IFN-γ are required for apoptosis but not neovascularization. Insignificant differences in the microvessel growth from
the aortic ring Matrigel assay between WT and IL-6–, IFN-γ–, and
TNF-α–deficient BMMCs suggest that mast cell mediators other
than IL-6, IFN-γ, and TNF-α modulate neovascularization in this
assay even though IFN-γ, IL-6, and TNF-α have been implicated in
angiogenesis. In fact, mast cell–derived bFGF, angiopoietin-1, chymase/tryptase, and a number of other proinflammatory cytokines
and chemokines (45) have been implicated in angiogenesis. These
mast cell mediators may have obscured the effect of mast cell IL-6,
IFN-γ, and TNF-α in our in vitro assays (Figure 6, A–C).
Pharmacologic regulation of mast cell activation and degranulation directly controlled AAA formation in mice (Figure 4, F and G).
These data not only strengthen the hypothesis that mast cells are
essential mediators of AAA pathogenesis but also suggest that
treatments blocking mast cell degranulation may prevent or delay
AAA progression in humans. Compound 48/80 has been widely
used to degranulate mast cells in live animals (46). Although the
detailed mechanisms of how C48/80 activates mast cells need to
be investigated further, recent observations suggest that C48/80
acts on mast cells via activation of phospholipase D (47) and Gαi3
G protein subunits (48) to trigger the release of histamine as well as
other granule components including cathepsins and MMP-activating chymases or cytokines, which may influence neighboring vascular cells. This hypothesis is supported by the findings of increased
cysteine protease and MMP activities, elevation of AAA tissue IFN-γ
and IL-6, and enhanced medial elastin degradation in aortic tissues
isolated from C48/80-treated mice (Figure 4). In contrast, DSCG is
a drug widely used in the treatment of asthmatic patients. Observations from in vitro tests and animal models show that the effect
of DSCG is related to mast cell stabilization. Importantly, this
compound reduces mouse AAA by 40% (Figure 4). Impaired AAA
in DSCG-treated mice is likely due to reduced release of mast cell
granule contents. This hypothesis is consistent with reduced AAA
lesion cysteine protease and MMP activities and IFN-γ and IL-6 levels found in DSCG-treated mice (Figures 4 and 5).
While this study provides evidence that mast cells regulate AAA
formation, it also leaves several important questions unanswered.
First, depletion of neutrophils in mice impairs elastase perfusion–
induced AAA (2), and mice lacking T lymphocytes have protection from CaCl2-induced AAA (3). Determination of whether lack
of mast cells in the current study affected the function of either
neutrophils or T lymphocytes will require further investigation.
Although we did not find significant differences of elastase activity of neutrophils from WT and KitW-sh/KitW-sh mice, unrecognized
interactions between these cell types may exist. Second, it remains
unknown what mediated the increased number of mast cells in
the injured aortas following elastase perfusion. Five weeks after
reconstitution, we detected few if any mast cells in the aortas. In
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contrast, elastase perfusion enhanced mast cell numbers in the
aortas. One possible explanation is that elastase perfusion induces
aortic wall SMC expression of chemokines MCP-1 and RANTES
(49), which may attract mast cells (50). Further, elastase perfusion
may generate elastin degradation products that signal fibroblast,
monocyte, and macrophage chemotaxis (51). Delineation of the
exact mechanism will require further investigation. Third, mast
cell–mediated neovascularization and SMC apoptosis remain
poorly understood. Although our data suggest that SMC apoptosis
involves mast cell–derived IFN-γ and IL-6, whether these cytokines
regulate SMC apoptosis directly or indirectly remains unknown.
Our prior study demonstrated that mast cell IFN-γ and IL-6 augment SMC and EC expression of cysteine proteases (19), which
participate in cell apoptosis (52). IFN-γ and IL-6 from mast cells
may have induced cathepsin expression and further led to SMC
apoptosis, a hypothesis that has not been tested in the current
study. Fourth, it remains uncertain whether increased expression
and activities of cathepsins and MMP in AAA lesions (Figure 5)
come from mast cells or other vascular cells. Mast cells contain
large quantities of cathepsins (53) and mast cell chymases that participate importantly in MMP activation (11). However, mast cell
cytokines (e.g., IL-6 and IFN-γ) are known stimulators of cathepsin
and MMP expression, and our previous study (19) and the current
study demonstrate concurrently their importance in arterial wall
remodeling. Therefore, it is possible that mast cells contribute to
AAA by releasing both proteases and cytokines, a hypothesis that
requires further investigation.
In summary, data from this study establish that mast cells play
a role in the development of AAA by affecting matrix-degrading
protease expression, medial SMC apoptosis, and microvessel growth.
More importantly, our data suggest a novel and effective therapeutic
strategy to control human AAA progression by preventing release of
mast cell products using mast cell–stabilizing compounds.
.FUIPET
AAA production. Eight- to ten-week-old male WT mice (from The Jackson
Laboratory, C57BL/6 background) and male KitW-sh/KitW-sh mice (C57BL/6
background) (17, 21) were used for aortic elastase perfusion, as detailed
elsewhere (4). Aortic diameters were measured before the surgery (day
–1), immediately following elastase perfusion (day 0), and 7, 14, and
56 days after perfusion. Abdominal aortas were harvested at each time
point. Lumen diameters were determined by measuring the lumen perimeters of cross sections of frozen aortas.
To produce AAA by periaortic chemical injury, 8-week-old male mice
were used for aorta CaCl2 injury as described (5). Aortic diameters were
measured before CaCl2 application and 6 weeks after the injury.
To harvest AAA tissues, after measuring the aortic diameter and collecting the blood, we removed the aortic zone of maximal expansion, either
directly freezing the tissue for protein extraction or OCT embedding for
cross section preparation. Immunohistological analysis used 6-μm sections while in situ elastin zymography used 8-μm cross sections. All mouse
experiments were performed under a protocol preapproved by the Animal
Research Committee of Harvard Medical School.
BMMC preparation and reconstitution. WT (C57BL/6), IFN-γ –/– (congenic C57BL/6, N10), IL-6–/– (congenic C57BL/6, N11), and TNF-α–/–
(C57BL/6*129/Sv, N1) mice were obtained from The Jackson Laboratory.
TNF-α–/– mice were backcrossed to a congenic C57BL/6 background (N10).
Bone marrow was isolated from these mice for BMMC differentiation for
5 weeks in the presence of recombinant murine IL-3 (PeproTech) and murine
stem cell factor (PeproTech) as reported (21). At this time, the cell popula-
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tions consisted of more than 95% mast cells as assessed by the presence of
metachromatic granules in toluidine blue–stained cells and FACS analysis for the disappearance of progenitor cell marker stem cell antigen-1. To
reconstitute BMMCs in vivo, the tail veins of 5-week-old male KitW-sh/KitW-sh
mice were injected with BMMCs (1 × 107 cells/mouse). Mice were perfused
with elastase to produce AAA 5 weeks after reconstitution.
Mast cell activation and stabilization in vivo. C48/80 activated the mast cells
in WT mice, and DSCG stabilized the mast cells in WT mice. After mice
(C57BL/6, male, 10 weeks old) recovered from elastase perfusion surgery
(day 0), they received the first i.p. injection of C48/80 (Sigma-Aldrich,
4 mg/kg/d) or DSCG (Sigma-Aldrich, 25 mg/kg/d). Each animal received
daily injection for the duration of the experiment thereafter (14 days).
Mast cell content measurement. Immunostaining with rabbit anti-mouse
mMCP-4 antibody (1:150) determined the mast cell number on aortic sections (19). Antibody specificity was confirmed using WT mouse AAA sections immunostained with rabbit preimmune serum and KitW-sh/KitW-sh mouse
aortic sections immunostained with the mMCP-4 antibody at the same antibody dilution. The total number of mMCP-4-positive cells on each section
were counted manually and blindly, and the total area was determined using
computer-assisted image analysis (Image-Pro Plus; MediaCybernetics).
Immunohistochemistry, ELISA, and lesion characterization. Frozen sections
(6 μm) were stained for macrophages (Mac-3), T cells (CD3), SMCs (α-actin),
ECs (CD31), mast cells (mMCP-4), elastin (Verhoeff–van Gieson), and IFN-γ
as described previously (19, 26). Lesion apoptotic cells were determined
with the In situ Apoptosis Detection kit according to the manufacturer’s
instructions (Chemicon International). Elastin degradation and lesion
SMC content were graded according to the grading keys shown in Figure 2,
C and D. To determine lesion IL-6 levels, frozen aortas were pulverized for
protein extraction in a pH 7.5 buffer containing 50 mM NaAc and 1% Triton X-100. Protein concentration was determined with a BCA kit (Bio-Rad)
and IL-6 levels measured by ELISA (R&D Systems). All immunostained
cells were counted or calculated blindly by at least 2 observers.
Cysteine protease active site labeling and gelatin gel in situ zymogram. Pulverized
aortic tissues were lysed in a pH 5.5 buffer. The cysteine protease activity
in tissue lysates was determined with [125I]JPM labeling (2 μg protein/lane)
(29), and the MMP activity was assessed by in-gel gelatinase zymogram assay
(5 μg protein/lane) as described (30). Equal protein loading (7 μg protein/
lane) was confirmed by SDS-PAGE followed with Coomassie staining.
Mast cell degranulation, aortic ring assay, and SMC apoptosis assay. In vitro–differentiated BMMCs were degranulated with mouse anti-DNP IgE monoclonal antibody as described previously (54). Degranulation efficiency was
calculated as follows: (experimental supernatant − control supernatant)/
(experimental supernatant + experimental cell lysates supernatant).
An aortic ring assay was used to test mast cell function in angiogenesis.
In brief, a 96-well plate was coated with 50 μl of Matrigel (BD Biosciences).
A 1-mm–long mouse aortic ring was laid on the top of the Matrigel and
covered with 100 μl of Matrigel. After solidification, 100 μl of RPMI
(10% FBS) with or without 100 μl of degranulated BMMC supernatant
was added to each well. After 7–10 days of culture, the aortas were photographed and the endothelial outgrowth was analyzed using Image-Pro Plus
software. To confirm a microvessel phenotype of sprouts from the aortic
ring, a Matrigel containing aortic ring and sprouts was embedded in OCT
followed by sectioning and immunostaining with CD31.
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